Composition of Optomed’s Nomination Board

Report this content

Optomed Plc     Stock Exchange Release             8th January 2020 at 10 a.m., Helsinki

Composition of Optomed’s Nomination Board

According to Optomed’s shareholder register of 2 January 2020, the shareholders represented in the shareholders’ Nomination Board are Jun Wu’s controlled entities (Alnair Investments, Cenova China Healthcare Fund IV and Shanghai Cenova Innovation Venture Fund (Limited Partnership)), Aura Capital Oy and Mandatum Life Insurance Company. These shareholders have appointed the following persons to the Nomination Board:

  • Hai Wu, Jun Wu’s controlled entities
  • Jarmo Malin, Aura Capital Oy
  • Ville Talasmäki, Mandatum Life Insurance Company
  • Petri Salonen, Chairman of Optomed’s Board of Directors

Petri Salonen, Chairman of Optomed’s Board of Directors, will serve as the Nomination Board's expert member.

According to
the resolution of Optomed General Meeting, the Optomed Nomination Board 2020 consists of the representatives of Optomed three largest shareholders as of the first trading day of the year, and the Chairman of the Board of Directors as an expert member. Should a shareholder not wish to exercise the nomination right, the right shall be transferred to the next largest shareholder who otherwise would not be entitled to nominate a member. The largest five shareholders were:

  1. Jun Wu’s controlled entities
  2. Universal Investments
  3. Robert Bosch Venture Capital GmbH
  4. Aura Capital Oy
  5. Mandatum Life Insurance Company

Universal Investments and Robert Bosch Venture Capital GmbH resolved not to utilize their nomination right.

The Nomination Board is to prepare proposals on the composition and members of the Board of Directors and their remuneration for the next Annual General Meeting

Optomed Plc

Further enquiries

Petri Salonen, Chairman of the Board, Optomed Plc,

Sakari Knuutti, CLO, Optomed Plc,


Nasdaq Helsinki Ltd

Principal media

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 52 international patents protecting the technology. In 2018, Optomed’s revenue reached EUR 12.7 million and pro forma revenue with the acquisition of Commit; Oy amounted to EUR 14.5 million. At the end of September 2019, Optomed employed 105 professionals.